Government of India will partner with Coalition for Epidemic Preparedness Innovations (CEPI) and pharma company Panacea Biotec, for developing a new Covid Vaccine.


  • They will develop vaccine candidates to provide broad protection against SARS-COV-2 variants as well as other beta coronaviruses.
  • CEPI’ll be partnering with a consortium comprising of Translational Health Science and Technology Institute (THSTI) which is an autonomous institute of Department of Biotechnology under Ministry of Science and Technology and Panacea Biotec.

Development ofMulti-epitope
CEPI’ll provide funding of over to USD 12 million for supporting the development ofmulti-epitope, advance manufacturing process and nanoparticle- based vaccine candidates.
For this, lead antigen will be designed and named through evidence-of- conception preclinical studies. Following this, CEPI’ll undertake initial clinical development through Phase 1 or 2 of studies.
Blueprint Priority Conditions
WHO’s blueprint priority diseases include

  1. Middle East respiratory syndrome- related coronavirus (MERS-CoV)
  2. Severe acute respiratory pattern coronavirus 2 (SARS-CoV-2)
  3. Nipah virus
  4. Lassa fever virus
  5. Rift Valley fever virus
  6. Chikungunya virus and
  7. Gypothetical, unknown pathogen “ Disease X”.

Related Articles